Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene

• Authors: M. Baranska , K. Lewandowski , M. Gniot , M. Iwola , Lewandowska. , M. Komarnicki
• Languages of publication: EN

Abstracts

EN

Point mutations of bcr-abl tyrosine kinase are the most frequent causes of imatinib resistance in chronic myeloid leukaemia (CML) patients. In most CML cases with BCR-ABL mutations leading to imatinib resistance the second generation of tyrosine kinase inhibitors (TKI- e.g. nilotinib or dasatinib) may be effective. Here, we report a case of a CML patient who during imatinib treatment did not obtain clinical and cytogenetic response within 12 months of therapy. The sequencing of BCR-ABL kinase domains was performed and revealed the presence of a F359I point mutation (TTC-to-ATC nucleotide change leading to Phe-to-Ile amino acid substitution). After 1 month of nilotinib therapy a rapid progression of clinical symptoms was observed. In the presence of the F359I point mutation only dasatinib treatment overcame imatinib and nilotinib resistance.

Keywords

EN

BCR-ABL ONCOGENE; DIRECT SEQUENCING; KINASE INHIBITOR; MUTATION; MYELOID LEUKEMIA

Discipline

• GENETICS: GENETICS

• Publisher: Institute of Plant Genetics, Polish Academy of Sciences
• Journal: Journal of Applied Genetics
• Year: 2008
• Volume: 49
• Issue: 2
• Pages: 201-203

Contributors

author

M. Baranska

author

K. Lewandowski

author

M. Gniot

author

M. Iwola

author

Lewandowska.

author

M. Komarnicki

• Document Type: ARTICLE
• Publication order reference: Marta Baranska, Department of Hematology, Poznan University of Medical Sciences, Szamarzewskiego 84, 60?569 Poznan, Poland